Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Biogen to focus on...

    Biogen to focus on core neuro business while spinning off Hemophilia drug trade

    Written by savita thakur thakur Published On 2016-05-04T09:19:55+05:30  |  Updated On 4 May 2016 9:19 AM IST
    Biogen to focus on core neuro business while spinning off Hemophilia drug trade

    Biogen Inc plans to spin off its hemophilia drug business as a publicly traded company, leaving the drugmaker to focus on developing drugs for neuro-degenerative diseases, the company said on Tuesday.


    Biogen said it considered a number of alternatives including a sale before deciding to split the business in a tax-free transaction, which it said would deliver the most value to its shareholders.


    The new company will include treatments Eloctate and Alprolix for hemophilia A and B, which had total sales of $554.2 million in 2015, about 5 percent of Biogen's revenue. Hemophilia is a group of hereditary genetic disorders that impairs the body's ability to control blood clotting.


    Biogen began a sweeping restructuring program in October to cut costs and focus on core areas such as neurology and autoimmune diseases. In April, Reuters reported that it was looking at selling the hemophilia assets.


    After that report, Citi analyst Robyn Karnauskas said the business could be worth $4.8 billion to $6.4 billion.


    Biogen expects the transaction to occur by the end of this year or early next year.


    Biogen will focus on developing drugs for neuro degenerative diseases such as multiple sclerosis, spinal muscular atrophy (SMA), Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and neuropathic pain. It will keep its bestselling MS drug, Tecfidera.


    The company's promising Alzheimer's drug candidate generated excitement last year after early data showed a reduction in amyloid plaque in the brain and some cognitive improvement.


    Biogen's collaboration on Eloctate and Alproprix with Swedish Orphan Biovitrum AB will continue, CEO George Scangos said during a conference call with analysts. The move to spin off the hemophilia drugs would have been premature 6 or 12 months ago, he said.


    "It's not really a shift in strategy. It is the fact that the business has matured. It is doing very well. It is profitable. It can stand on its own," Scangos said. The area of the company focused on hemophilia also has a pipeline of experimental products that need to be "aggressively" developed, he said.


    Biogen's executive vice president, pharmaceutical operations and technology, John Cox, will be the chief executive officer of the new company, which will be based in the Boston area, Biogen said.


    Biogen shares were largely unchanged in early trading at $274.52, versus their Monday close of $273.67.

    AlprolixALSAlzheimer's diseaseamyloid plaqueamyotrophic lateral sclerosisBiogenBiovitrum ABEloctateHemophilia A and BJohn Coxmultiple sclerosisneuro-degenerative diseasesParkinson's diseaseRobyn KarnauskasSMAspinal muscular atrophyTecfidera
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok